Pediatric myelodysplastic syndromes
- 124 Downloads
A new classification of myelodysplastic and myeloproliferative diseases in childhood has greatly facilitated the diagnosis of these uncommon disorders. Because hematopoietic stem cell transplantation (HSCT) can cure more than half of the affected children, palliative treatment strategies often applied in adult myelodysplastic syndrome (MDS) are of little importance in pediatric MDS. Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly.
KeywordsAcute Myeloid Leukemia Hematopoietic Stem Cell Transplantation Aplastic Anemia Myelodysplastic Syndrome Amifostine
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Edited by Jaffe EJ, Harris NL, Stein H, Vardiman JW. Lyon: International Agency for Research on Cancer; 2001.Google Scholar
- 2.Kardos G, Baumann I, Passmore SJ, et al.: Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003, 102:1997–2003. This paper reviews clinical courses observed in a large cohort of children with refractory cytopenia.PubMedCrossRefGoogle Scholar
- 3.Hasle H, Niemeyer CM, Chessells JM, et al.: A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17:277–282. This paper summarizes the present classification scheme employed in pediatric myelodysplastic syndrome.PubMedCrossRefGoogle Scholar
- 4.Passmore SJ, Chessells JM, Kempski H, et al.: Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003, 121:758–767. This paper describes a large cohort of pediatric patients with myelodysplastic syndrome.PubMedCrossRefGoogle Scholar
- 15.Niemeyer CM, Zecca M, Korthoff E, et al.: Allogeneic stem cell transplantation for children with advanced primary MDS: results from the EWOG-MDS study group employing a pretransplant preparative regimen with busulfan, cyclophosphamide, and melphalan [abstract]. Blood 2004, 104:632a.Google Scholar
- 20.Locatelli F, Zecca M, Duffner U, et al.: Busulfan, cyclophosphamide, and melphalan as pretransplant conditioning regimen for children with myelodysplasia (MDS) and juvenile myelomonocytic leukaemia (JMML). Interim analysis of the EWOGMDS/ EBMT prospective study. Leukemia 2002, 14:971.Google Scholar
- 21.List AF, Vardiman J, Issa JP, Dewitte TM: Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004, 297–317.Google Scholar
- 25.de Witte T, Hermans J, Vossen J, et al.: Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:620–630.PubMedCrossRefGoogle Scholar